SML3055
LY3009120
≥98% (HPLC)
别名:
1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea, DP 4978, DP-4978, DP4978, LY 3009120, LY-3009120, N-(3,3-Dimethylbutyl)-N′-[2-fluoro-4-methyl-5-[7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl]phenyl]urea
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C23H29FN6O
化学文摘社编号:
分子量:
424.51
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear (warmed)
storage temp.
2-8°C
SMILES string
CC1=CC(F)=C(C=C1C2=C(N=C3N=C(N=CC3=C2)NC)C)NC(NCCC(C)(C)C)=O
InChI
1S/C23H29FN6O/c1-13-9-18(24)19(29-22(31)26-8-7-23(3,4)5)11-16(13)17-10-15-12-27-21(25-6)30-20(15)28-14(17)2/h9-12H,7-8H2,1-6H3,(H2,26,29,31)(H,25,27,28,30)
InChI key
HHCBMISMPSAZBF-UHFFFAOYSA-N
Biochem/physiol Actions
LY3009120 is an orally active, potent and selective pan-RAF type II inhibitor (IC50 = 4.3 nM/CRAF (c-Raf, Raf-1), 5.8 nM/BRAF(V600E), 15 nM/BRAF (b-Raf) by kinase assay with 1 mM ATP; IC50 = 44 nM/ARAF, 31-47 nM/BRAF, 42 nM/CRAF, >1 μM/155 other kinases by cell-based KiNativ affinity binding assay). LY3009120 inhibits RAF-dependent proliferation in cancer cultures (A375/HCT116 IC50 = 9.2/220 nM) and exhibits anti-tumor efficacy in a rat BRAF V600E ST019VR PDX model in vivo (15-30 mg/kg b.i.d. p.o.).
Orally active, potent and selective pan-RAF type II inhibitor with anti-cancer efficacy in cultures and in vivo.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML3055-10MG | 04065266142143 |
| SML3055-50MG | 04065266142150 |